GenePOC Announces an Exclusive Distribution Agreement with Cardinal Health covering the US market

Québec, Canada (ots) - GenePOC announces the signing of an
exclusive distribution agreement with Cardinal Health to become its
commercial partner in the United States.

GenePOC, Inc. (GenePOC), a member of the Debiopharm Group, is
proud to announce that it has signed an exclusive distribution
agreement with Cardinal Health to become its commercial partner in
the United States to sell the revogene(TM) instrument and associated
GenePOC(TM) assays. This is a key milestone in the development of
GenePOC's commercial operations.

"We are extremely proud to announce this collaboration", said
Patrice Allibert, CEO of GenePOC, he continued: "Cardinal Health is
the perfect match for GenePOC, holding an impressive track record in
improving patient life and laboratory efficiency. The GenePOC
solution represents a unique market breakthrough, addressing untapped
increasing demand for the use of Molecular Testing in a wide range of
clinical and laboratory settings. We are confident that this new
partnership will support us in making a real difference in the
diagnosis of infectious diseases by being closer to the patient. We
further believe this distribution agreement will pave the way for
GenePOC to become a key Molecular Testing player in the mid-size
molecular lab, the satellite lab, and all the way into the Point of
Care market."

The revogene(TM) is a fully-automated, portable standalone
instrument. It enables testing of single-use microfluidic cartridges,
or PIEs, with its proprietary fluorescence-based quantitative
polymerase chain reaction (qPCR) platform to deliver an accurate
diagnosis.

Both the revogene(TM) instrument and it's first to market
GenePOC(TM) GBS LB assay recently received FDA clearance.

About GenePOC

GenePOC is a company that specializes in the development of
diagnostic devices which enable the prevention and detection of
infectious diseases. The company aims to become the market leader in
the rapid microbial testing at the point of care (POC). GenePOC is a
member of the Debiopharm Group. GenePOC's revogene(TM) instrument is
available in the US, European and, Middle Eastern markets with a
rapidly expanding test menu.

Further information: www.genepoc-diagnostics.com

About Debiopharm Group

Debiopharm Group(TM) is a Swiss-headquartered global
biopharmaceutical group including five companies active in the life
science areas of drug development, GMP manufacturing of proprietary
drugs, diagnostic tools and investment management.

For more information, please see www.debiopharm.com We are on
Twitter. Follow @DebiopharmNews at http://twitter.com/DebiopharmNews

Pressekontakt:
Contact at Debiopharm International SA
Christelle Tur
Communications Coordinator
christelle.tur@debiopharm.com
Tel.: +41 (0)21 321 01 11

Contact at GenePOC
Patrice Allibert, Ph.D
CEO
patrice.allibert@genepoc.ca
Tel.: +1-418-650-3535

Original-Content von: Debiopharm International SA, übermittelt durch news aktuell